Mesalazine
- Generic Name
- Mesalazine
- Brand Names
- Apriso, Asacol, Canasa, Delzicol, Lialda, Mezavant, Pentasa, Rowasa, Salofalk, Zaldyon
- Drug Type
- Small Molecule
- Chemical Formula
- C7H7NO3
- CAS Number
- 89-57-6
- Unique Ingredient Identifier
- 4Q81I59GXC
- Background
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease . Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stabil...
- Indication
适用于溃疡性结肠炎和克罗恩病（Crohn病）。
- Associated Conditions
- Acute Ulcerative Colitis, Crohn's Disease Relapse, Crohn's Ileocolitis, Mild to Moderate Ulcerative Colitis, Proctitis, Proctitis, Ulcerative, Proctosigmoiditis, Ulcerative Colitis in Remission, Mild Ulcerative Colitis, Mild to moderate distal ulcerative colitis, Moderate Ulcerative colitis
- Associated Therapies
- -
Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation
Fenofibrate, a PPARα agonist, significantly improves clinical outcomes and reduces inflammation in mild to moderate ulcerative colitis (UC) patients when combined with mesalamine, according to a randomized, double-blind, controlled clinical study. The study found that fenofibrate enhances the digestive domains of the IBDQ-32, reduces inflammatory markers like NLRP3 and fecal calprotectin, and upregulates SIRT1 and AMPK. The combination therapy is safe and tolerable, suggesting further investigation for UC treatment.
Gastrointestinal Diseases Therapeutics Market to Grow by USD 18.5 Billion from 2024-2028
The Global Gastrointestinal Diseases Therapeutics Market is projected to grow by USD 18.5 billion from 2024-2028, driven by increasing disease incidence and nutritional therapies. Key players include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, and others. High treatment costs pose a challenge.
Pharma stocks: Nomura gives 'Buy' to Lupin remains 'Neutral' on others
Indian pharma giants focus on quality over quantity, with complex product filings increasing. US generics sales show slight growth, and regulatory challenges ease. Nomura recommends Lupin for its upcoming launches and stable market shares, while noting setbacks. Sun Pharma's specialty segment growth slows, and Dr Reddy's faces market share declines. Cipla and Zydus Lifesciences show growth but face inspection and competition challenges.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath